Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1984 1
1985 1
1991 1
1992 2
1994 1
1996 2
1998 1
2000 6
2002 1
2003 5
2004 1
2005 4
2006 2
2007 3
2008 4
2009 2
2010 4
2011 6
2012 5
2013 3
2014 1
2015 1
2016 2
2017 2
2018 4
2019 6
2020 5
2021 5
2022 2
2023 3
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Occult Lung Non-Small Cell Carcinoma"
Page 1
Oligometastasis: Past, Present, Future.
Gutiontov SI, Pitroda SP, Weichselbaum RR. Gutiontov SI, et al. Int J Radiat Oncol Biol Phys. 2020 Nov 1;108(3):530-538. doi: 10.1016/j.ijrobp.2020.02.019. Int J Radiat Oncol Biol Phys. 2020. PMID: 32976785 Review.
We then transition to a discussion of the clinical data that led to the formulation of the oligometastatic hypothesis, delving in some detail into the clinical factors associated with improved outcomes in the setting of local therapy-whether surgical or radiotherape …
We then transition to a discussion of the clinical data that led to the formulation of the oligometastatic hypothesis, delving in som …
Adjuvant therapy in non-small cell lung cancer: future treatment prospects and paradigms.
Carbone DP, Felip E. Carbone DP, et al. Clin Lung Cancer. 2011 Sep;12(5):261-71. doi: 10.1016/j.cllc.2011.06.002. Epub 2011 Aug 10. Clin Lung Cancer. 2011. PMID: 21831720 Review.
There is a high risk of relapse after curative-intent resection for even early-stage non-small cell lung cancer (NSCLC), and thus adjuvant chemotherapy has been explored with the goal of eliminating occult metastases and consequently reducing th …
There is a high risk of relapse after curative-intent resection for even early-stage non-small cell lung cancer …
Systematic endoscopic staging of mediastinum to guide radiotherapy planning in patients with locally advanced non-small-cell lung cancer (SEISMIC): an international, multicentre, single-arm, clinical trial.
Steinfort DP, Kothari G, Wallace N, Hardcastle N, Rangamuwa K, Dieleman EMT, Lee P, Li P, Simpson JA, Yo S, Bashirdazeh F, Nguyen P, Jennings BR, Fielding D, Crombag L, Irving LB, Yasufuku K, Annema JT, Ost DE, Siva S. Steinfort DP, et al. Lancet Respir Med. 2024 Jun;12(6):467-475. doi: 10.1016/S2213-2600(24)00010-9. Epub 2024 Mar 12. Lancet Respir Med. 2024. PMID: 38490228 Clinical Trial.
BACKGROUND: Systematic mediastinal lymph node staging by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) improves accuracy of staging in patients with early-stage non-small-cell lung cancer (NSCLC). However, patients with l …
BACKGROUND: Systematic mediastinal lymph node staging by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) improv …
Tumors of unknown origin.
Greco FA, Hainsworth JD. Greco FA, et al. CA Cancer J Clin. 1992 Mar-Apr;42(2):96-115. doi: 10.3322/canjclin.42.2.96. CA Cancer J Clin. 1992. PMID: 1540854 Free article. Review.
A therapeutic trial remains the only method to determine if patients have responsive tumors, and several patients who do not conform to a defined subset do respond to cisplatin-based chemotherapy. ...Improved therapy for these patients will probably await advances in the t …
A therapeutic trial remains the only method to determine if patients have responsive tumors, and several patients who do not conform …
18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer.
Takahashi Y, Suzuki S, Matsutani N, Kawamura M. Takahashi Y, et al. Thorac Cancer. 2019 Mar;10(3):413-420. doi: 10.1111/1759-7714.12978. Epub 2019 Jan 21. Thorac Cancer. 2019. PMID: 30666803 Free PMC article. Review.
One in four non-small cell lung cancer (NSCLC) patients are diagnosed at an early-stage. Following the results of the National Lung Screening Trial that demonstrated a survival benefit for low-dose computed tomography screening in high-ri …
One in four non-small cell lung cancer (NSCLC) patients are diagnosed at an early-stage. Following the results o …
Adjuvant therapy of resected non-small-cell lung cancer.
Socinski MA. Socinski MA. Clin Lung Cancer. 2004 Nov;6(3):162-9. doi: 10.3816/CLC.2004.n.029. Clin Lung Cancer. 2004. PMID: 15555217 Review.
Surgical resection of early-stage non-small-cell lung cancer (NSCLC) remains the standard of care in patients fit for surgery. ...The use of adjuvant cisplatin-based therapy did not show a survival advantage in the Adjuvant Lung Project Italy st …
Surgical resection of early-stage non-small-cell lung cancer (NSCLC) remains the standard of care in patients fi …
Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer.
Blackstock AW, Govindan R. Blackstock AW, et al. J Clin Oncol. 2007 Sep 10;25(26):4146-52. doi: 10.1200/JCO.2007.12.6581. J Clin Oncol. 2007. PMID: 17827465 Review.
A third of patients with newly diagnosed non-small-cell lung cancer (NSCLC) have locally advanced disease not amenable for curative resection. ...The widespread use of positron emission tomography (identifying those with occult distant metastati …
A third of patients with newly diagnosed non-small-cell lung cancer (NSCLC) have locally advanced disease not am …
Follow-up and surveillance of the lung cancer patient following curative-intent therapy.
Colice GL, Rubins J, Unger M; American College of Chest Physicians. Colice GL, et al. Chest. 2003 Jan;123(1 Suppl):272S-283S. doi: 10.1378/chest.123.1_suppl.272s. Chest. 2003. PMID: 12527585 Review.
The following two distinctly different issues should be taken into account when planning patient care following curative-intent therapy for lung cancer: adequate follow-up to manage complications related to the curative-intent therapy; and surveillance to detect recurrence …
The following two distinctly different issues should be taken into account when planning patient care following curative-intent therapy for …
Treatment of stage IIIA non-small cell lung cancer.
Robinson LA, Wagner H Jr, Ruckdeschel JC; American College of Chest Physicians. Robinson LA, et al. Chest. 2003 Jan;123(1 Suppl):202S-220S. doi: 10.1378/chest.123.1_suppl.202s. Chest. 2003. PMID: 12527580 Review.
Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and also includes T3N1 patients. Presentations of disease range from apparently resect …
Stage IIIA non-small cell lung cancer represents a relatively heterogeneous group of patients with metastatic di …
Estimated impact of LDCT-identified stage IA non-small-cell lung cancer on screening efficacy.
Reich JM. Reich JM. Lung Cancer. 2006 Jun;52(3):265-71. doi: 10.1016/j.lungcan.2006.02.007. Epub 2006 Apr 17. Lung Cancer. 2006. PMID: 16616394 Review.
About one-third of individuals radiographically diagnosed with surgical-pathological stage IA non-small-cell lung cancer (IA-NSCLC) harbor occult metastases that prove lethal. A comparison of the projected outcome of CT-diagnosed IA-NSCLC with a …
About one-third of individuals radiographically diagnosed with surgical-pathological stage IA non-small-cell lung …
79 results